menu
    • menu

    Company profile for Denali Therapeutics

    NEW Drugs in Dev: 16
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Denali was founded by scientists, drug developers and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for patients suffering from neurodegenerative disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Denali TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    151 Oyster Point Blvd - South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.denalitherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Denali Delivers ‘Welcome Positive’ for Rare Disease Space
    Denali Delivers ‘Welcome Positive’ for Rare Disease Space

    26 Mar 2026

    // BIOSPACE

    https://www.biospace.com/fda/denali-delivers-welcome-positive-for-rare-disease-space-with-fdas-hunter-syndrome-nod

    BIOSPACE
    26 Mar 2026
    Share Share
    US FDA approves Denali's genetic disorder therapy for children
    US FDA approves Denali's genetic disorder therapy for children

    25 Mar 2026

    // PRESS RELEASE

    https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-us-fda-approval-avlayahtm

    PRESS RELEASE
    25 Mar 2026
    Share Share
    Denali’s Biologics Avlayah Receives Approval in US
    Denali’s Biologics Avlayah Receives Approval in US

    24 Mar 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761485

    FDA
    24 Mar 2026
    Share Share
    Denali’s Hunter Syndrome Drug Gains Focus After REGENXBIO Setback
    Denali’s Hunter Syndrome Drug Gains Focus After REGENXBIO Setback

    16 Mar 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/denalis-hunter-syndrome-candidate-in-the-spotlight-after-regenxbio-rejection

    BIOSPACE
    16 Mar 2026
    Share Share
    Denali Unveils LSD Advances at 2026 WORLD Symposium
    Denali Unveils LSD Advances at 2026 WORLD Symposium

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233366/0/en/Denali-Therapeutics-Presents-Enzyme-TransportVehicle-Progress-Across-Three-Clinical-Programs-for-Treatment-of-Lysosomal-Storage-Disorders-at-2026-WORLDSymposium.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Denali Therapeutics Showcases Enzyme Transportvehicle Programs
    Denali Therapeutics Showcases Enzyme Transportvehicle Programs

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230197/0/en/Denali-Therapeutics-To-Host-Webcast-Highlighting-Presentations-on-Enzyme-TransportVehicle-Programs-at-the-2026-WORLDSymposium.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search